CN111187826A - SMN1 gene detection primer group capable of eliminating SMN2 interference, kit and detection method - Google Patents
SMN1 gene detection primer group capable of eliminating SMN2 interference, kit and detection method Download PDFInfo
- Publication number
- CN111187826A CN111187826A CN202010058927.6A CN202010058927A CN111187826A CN 111187826 A CN111187826 A CN 111187826A CN 202010058927 A CN202010058927 A CN 202010058927A CN 111187826 A CN111187826 A CN 111187826A
- Authority
- CN
- China
- Prior art keywords
- fip
- smn2
- kit
- smn1
- interference
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100021947 Survival motor neuron protein Human genes 0.000 title claims abstract description 52
- 238000001514 detection method Methods 0.000 title claims abstract description 41
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 title claims abstract description 35
- 101150081851 SMN1 gene Proteins 0.000 title claims abstract description 23
- 239000000243 solution Substances 0.000 claims description 15
- 239000000654 additive Substances 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 11
- 239000007853 buffer solution Substances 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 7
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 6
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 claims description 6
- 239000011565 manganese chloride Substances 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 239000013642 negative control Substances 0.000 claims description 6
- 229960002378 oftasceine Drugs 0.000 claims description 6
- 239000013641 positive control Substances 0.000 claims description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical group CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 239000007984 Tris EDTA buffer Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 3
- 239000012498 ultrapure water Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims 1
- 230000003321 amplification Effects 0.000 abstract description 24
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 24
- 230000035772 mutation Effects 0.000 abstract description 14
- 238000007397 LAMP assay Methods 0.000 abstract description 11
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 20
- 208000002320 spinal muscular atrophy Diseases 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- 206010064571 Gene mutation Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 101150015954 SMN2 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000037435 normal mutation Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an SMA gene detection primer group, a kit and a detection method capable of eliminating interference of SMN2, wherein two different bases of SMN1 and SMN2 are respectively designed at the 3 'ends of FIP and BIP primers, and auxiliary mutation bases are designed at the penultimate base of the 3' ends of the FIP and BIP primers, so that the specificity of LAMP amplification is enhanced. The influence of SMN2 on amplification is eliminated through BIP-W, and whether SMN1 is mutated or not is distinguished by FIP-W and FIP-M, so that the genotype of the SMN1 gene of the sample to be detected is accurately judged. The detection method adopts a loop-mediated isothermal amplification technology and has extremely high sensitivity, so that a small amount of oral swabs of a patient can be used as a template for amplification after being boiled to release DNA, and a blood sample does not need to be collected.
Description
Technical Field
The invention belongs to the technical field of molecular biology, and particularly relates to an SMA gene detection primer group capable of eliminating SMN2 interference, a kit and a detection method.
Background
Spinal Muscular Atrophy (SMA) is a relatively common autosomal recessive genetic disorder characterized primarily by muscle weakness and muscle atrophy caused by degenerative degeneration and loss of motor neurons at the anterior horn of the Spinal cord. The disease rate of SMA is 1/10000-1/6000, and the carrying rate is 1/50-1/40. The pathogenesis of SMA is mainly caused by hereditary neuromuscular disease caused by functional defect of SMN protein due to mutation of the 6 th base of the No. 7 exon on a survival gene 1 (SMN 1) of motor neurons at 5q13.2 from C to T. SMN is a widely expressed housekeeping protein and can be used as a subunit to be combined with Sm protein to recruit Sm nucleoprotein and micronucleus ribonucleic acids (snRNAs) to assemble into ribonucleoprotein complexes (snRNPs) in the form of SMN complexes. In addition, SMN2 is present in the body of each person as a modifier of Spinal Muscular Atrophy (SMA), and the gene sequences of SMN2 and SMN1 are different only by individual bases (as shown in fig. 2), so that SMN2 has a large interference effect on gene screening during detection, and it is often difficult to distinguish SMN1 gene mutation carriers from homozygous normal persons. Although effective drugs against SMA have been developed, there is still a need to find early treatment, especially better treatment for patients with SMA in infancy, at a very high cost. Therefore, prenatal screening of SMN1 genotype is important to reduce the wind direction of SMA in newborns.
At present, the gene detection technology for SMA is mainly based on Polymerase Chain Reaction (PCR), real-time quantitative PCR (RT-PCR), restriction fragment length polymorphism polymerase chain reaction (PCR-RFLP), single strand conformation polymorphism (PCR-SSCP), multiple ligation probe amplification technology (MLPA), fluorescence in situ hybridization technology (FISH), and the like, and then sequence analysis is performed by combining with nucleic acid sequencing technology. However, all of the above techniques are in vitro amplification based on the PCR technique, but the detection result may fail to some extent due to the sensitivity limitation of the PCR technique. On the other hand, in the PCR technology, because there is a certain probability of amplification variation in the amplification process of DNA Polymerase, there is also a certain false positive rate. The technology has long detection time and high cost, and is difficult to popularize in primary medical units.
The loop-mediated isothermal amplification (LAMP) technology has been widely used for detecting pathogenic microorganisms at present due to its low requirements for detection equipment, simple operation and high sensitivity. In recent years, the LAMP method is also studied and reported to detect gene mutation, but the LAMP method still has obvious defects. For example, patent document CN 105861690A combines the LAMP technique with the principle that a probe prepared from Peptide Nucleic Acid (PNA) and DNA or RNA can form a stable complex, and a single base mutation can cause a large Tm value change in the complex. However, the existing peptide nucleic acid synthesis technology is still not mature, the purity of synthesized PNA can only reach 90% -95%, meanwhile, the synthesis cost of peptide nucleic acid is high, the cost for synthesizing 50nmol is as high as about 5000-6000 yuan, the detection cost is high, and the popularization difficulty is high.
Disclosure of Invention
Aiming at the technical problems, the invention provides an SMA gene detection primer group, a kit and a detection method capable of eliminating the interference of SMN2, and solves the problems of long time consumption, high cost, high equipment dependence and the like of the existing gene mutation detection technology.
In order to achieve the purpose, the invention adopts the following technical scheme:
a primer group for SMN1 gene detection capable of eliminating SMN2 interference, wherein the primer group comprises the following 7 primers;
F3：5’-GCTATCTATGTCTATATAGCTAT-3’；
B3：5’-GTTTTGGCATCAAAATTCTTTAAT-3’；
FIP-W:5’-TGCTGGCAGACTTACTCCTTAACTTTATTTTCCTTACAGGGTTVC-3’；
FIP-M:5’-TGCTGGCAGACTTACTCCTTAACTTTATTTTCCTTACAGGGTTVT-3’；
BIP-W:5’-TGAAAGTGAATCTTACTTTTGTAAAAGTTTTACATTAACCTTTCAACTTVT-3’；
LF：5’-GTGAGCACCTTCCTTCTTTTT-3’；
LB：5’-GTGGAAAACAAATGTTTTTGAAC-3’。
the invention also discloses a kit for detecting the SMN1 gene, which can eliminate the interference of the SMN2 and comprises the primer group.
Further, the kit also comprises Bst DNA Polymerase, dNTP, buffer solution, indicator and additive;
the buffer solution comprises Tris-HCl, KCl and (NH)4)2SO4、MgSO4And Tween-20; the indicator is SYBR Green I solution or Calcein solution and MnCl2A mixed solution of the solution; the additive comprises trehalose and BSA.
Preferably, the concentration of the primers F3 and B3 is the same and is 0.8-1.6 mu mol/L, the concentration of LF and LB is the same and is 1.6-3.2 mu mol/L, and the concentration of FIP-W, FIP-M, BIP-W is the same and is 1.6-3.2 mu mol/L;
preferably, the Bst DNA polymerase0.3-0.4U/microliter; the dNTP is 1.0-3.5 mmol/L; the buffer solution contains 10-50 mmol/L, KCl of Tris-HCl 10-100 mmol/L and (NH)4)2 SO 45 to 20mmol/L, MgSO4The buffer solution accounts for 0.1-0.5% of the buffer solution by mass of 6-10 mmol/L, Tween-20;
preferably, the concentration of SYBR Green I is 1X-5X; the Calcein and the MnCl2The concentration of the Calcein solution in the mixed solution is 10-30 mu mol/L, and the mixed solution is MnCl2The solution was 500. mu. mol/L.
Preferably, the trehalose in the additive is 0.1-0.3 mol/L, and the BSA is 0.2-1 mg/ml.
The invention also discloses a detection method of the SMN1 gene capable of eliminating the interference of the SMN2, which comprises the following steps:
placing the oral swab into 200 mul TE buffer solution, vortex and shake for 1min, and heating at 100 ℃ for 5min to obtain a template to be tested; the SMN1-W and SMN1-M genes were ligated to pUC57 vector, respectively, and diluted to 1 ng/. mu.l as positive controls; sterile ultrapure water was used as a negative control;
by utilizing LAMP technology, a template to be tested, a positive control and a negative control are respectively added into the kit system, and the whole reaction system reacts for 60 cycles under the conditions of 65 ℃ for 45sec and 65 ℃ for 15 sec; then, the reaction was carried out at 85 ℃ for 5min, and the genotype of the SMN1 gene was determined from the reaction curve.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention uses LAMP technology to locate the base to be detected at the 3 ' end of the primer, and artificially mutates the base at the adjacent position of the base to be detected, so that the DNA Polymerase can accurately identify the base to be detected at the 3 ' end of the primer in the amplification process, the identification capability of Bst DNA Polymerase on the 3 ' end of the primer is obviously improved, the design and the use of a probe are avoided, the detection cost is reduced, and the storage stability of a detection reagent is improved;
(2) the detection method adopts a loop-mediated isothermal amplification technology and has extremely high sensitivity, so that a small amount of oral swabs of a patient can be used as a template for amplification after being boiled to release DNA, and a blood sample does not need to be collected;
(3) according to the invention, DNA extraction operation is not required, the oral swab can be used as a template after being boiled, and the whole detection process only needs to add a small amount of oral swab crude extract and reaction buffer solution by combining a freeze-drying technology, so that the operation steps are greatly simplified;
(4) the invention realizes the rapid identification of the SMN1 gene homozygous mutation, homozygous normal mutation and heterozygous mutation by simultaneously detecting two different sites of SMN1 and SMN 2. And no special requirement is required for the detection equipment, and only one water bath kettle or other equipment capable of providing constant temperature conditions and one blue light lamp are needed. The technology realizes the real-time detection while realizing the accurate detection, and reduces the detection cost and the popularization difficulty.
Drawings
FIG. 1 is a schematic diagram of detection of point mutations in the kit of the present invention, wherein A: FIP-W amplifies wild-type SMN 1; b: FIP-M failed to amplify wild-type SMN 1; c: FIP-W fails to amplify mutant SMN 1; d: FIP-M can amplify mutant SMN 1; e: BIP-W amplification of SMN 1; f: BIP-W did not amplify SMN 2.
FIG. 2 shows the difference between SMN1 and SMN2 gene sequences.
FIG. 3 is a graph showing the results of detection in example 4, A: SMN1-W is amplified by FIP-W; b: FIP-M amplifies SMN 1-M; c: the FIP-W amplification sample 1 to be detected is homozygous and normal; d: the FIP-M amplification sample 2 to be detected is homozygous mutation.
Fig. 4 is a graph of the detection result of comparative example 1, a: SMN1-W is amplified by FIP-W; b: FIP-M amplifies SMN 1-M; c: the FIP-W amplification sample 1 to be detected is homozygous and normal; d: the FIP-M amplification sample 2 to be detected is homozygous mutation.
Fig. 5 is a graph of the test result of comparative example 2, a: SMN1-W is amplified by FIP-W; b: FIP-M amplifies SMN 1-M; c: the FIP-W amplification sample 1 to be detected is homozygous and normal; d: the FIP-M amplification sample 2 to be detected is homozygous mutation.
Fig. 6 is a graph of the test result of comparative example 3, a: SMN1-W is amplified by FIP-W; a: SMN1-M was amplified by FIP-W; b: FIP-M amplifies SMN 1-M; b: FIP-M amplifies SMN 1-W; c: FIP-W amplifies the sample 1 to be measured; c: FIP-M amplifies the sample 1 to be measured; d: FIP-W amplifies the sample 2 to be measured; d: FIP-M amplifies the sample 2 to be tested.
Fig. 7 is a graph of the test result of comparative example 4, a: SMN1-W is amplified by FIP-W; a: SMN1-M was amplified by FIP-W; b: FIP-M amplifies SMN 1-M; b: FIP-M amplifies SMN 1-W; c: FIP-W amplifies the sample 1 to be measured; c: FIP-M amplifies the sample 1 to be measured; d: FIP-W amplifies the sample 2 to be measured; d: FIP-M amplifies the sample 2 to be tested.
Detailed Description
The amplification primer used for detecting the non-recurrent mutation is called a wild-type primer, and is represented by W, such as FIP-W, and is used for detecting the wild-type gene primer of SMN1 of a suspected SMA patient. The amplification primer used to detect the occurrence of a mutation is referred to as a mutant primer and is denoted by M. The auxiliary mutant base is present in both the wild type primer and the mutant type primer, is the same base, and may be three bases other than the base itself, and may be T, C or G if the base itself is A.
The primer set of the present invention comprises 7 primers:
F3：5’-GCTATCTATGTCTATATAGCTAT-3’；
B3：5’-GTTTTGGCATCAAAATTCTTTAAT-3’；
FIP-W:5’-TGCTGGCAGACTTACTCCTTAACTTTATTTTCCTTACAGGGTTVC-3’；
FIP-M:5’-TGCTGGCAGACTTACTCCTTAACTTTATTTTCCTTACAGGGTTVT-3’；
BIP-W:5’-TGAAAGTGAATCTTACTTTTGTAAAAGTTTTACATTAACCTTTCAACTTVT-3’；
LF：5’-GTGAGCACCTTCCTTCTTTTT-3’；
LB：5’-GTGGAAAACAAATGTTTTTGAAC-3’。
wherein V is an auxiliary mutation base and is any one base of A, C, G, FIP-W is matched with F3, B3, BIP-W, LF and LB to be used as a primer group for detecting the wild SMN1-W gene, FIP-M is matched with F3, B3, BIP-W, LF and LB to be used as a primer group for detecting the mutant SMN1-M gene.
FIG. 1 is a schematic diagram showing the detection of point mutations in the detection method of the present invention. According to the invention, two different bases SMN1 and SMN2 are respectively designed at the 3 'ends of the FIP and BIP primers, and auxiliary mutation bases are designed at the penultimate base at the 3' ends of the FIP and BIP primers, so that the specificity of LAMP amplification is enhanced. The influence of SMN2 on amplification is eliminated through BIP-W, and whether SMN1 is mutated or not is distinguished by FIP-W and FIP-M, so that the genotype of the SMN1 gene of the sample to be detected is accurately judged.
The following embodiments of the present invention are provided, and it should be noted that the present invention is not limited to the following embodiments, and all equivalent changes based on the technical solutions of the present invention are within the protection scope of the present invention.
Example 1
The kit disclosed in this embodiment comprises: bst DNA Polymerase, dNTP, a primer group, a buffer solution, an indicator and an additive; wherein Bst DNA Polymerase is 0.32U/. mu.l, dNTP is 1.4mmol/L, and buffer solution is composed of 20mmol/L LTris-HCl, 10mmol/L (NH)4)2SO450mmol/L KCl, 0.1 percent of Tween-20 in mass portion and 8mmol/LMgSO in mass portion4The indicator is 2 XSSYBR Green I, and the additive is composed of 0.1mol/L trehalose and 0.5mg/ml BSA. The primer group comprises the following 7 primers:
F3：5’-GCTATCTATGTCTATATAGCTAT-3’；
B3：5’-GTTTTGGCATCAAAATTCTTTAAT-3’；
FIP-W:5’-TGCTGGCAGACTTACTCCTTAACTTTATTTTCCTTACAGGGTTVC-3’；
FIP-M:5’-TGCTGGCAGACTTACTCCTTAACTTTATTTTCCTTACAGGGTTVT-3’；
BIP-W:5’-TGAAAGTGAATCTTACTTTTGTAAAAGTTTTACATTAACCTTTCAACTTVT-3’；
LF：5’-GTGAGCACCTTCCTTCTTTTT-3’；
LB：5’-GTGGAAAACAAATGTTTTTGAAC-3’。
in the primer set of this example, the concentrations of F3 and B3 were the same and were both 0.4. mu. mol/L; the concentrations of LF and LB are the same and are 0.8 mu mol/L; the concentration of FIP-W, FIP-M, BIP-W was the same and was 1.6. mu. mol/L.
The kit of the embodiment is used for detecting the SMN1 gene, and specifically comprises the following steps:
preparing a DNA template: collecting two oral swabs of two persons, respectively placing the two oral swabs into TE buffer solution (10mM Tris-HCl pH 8.0, 1mM EDTA) for vortex oscillation for 1min, heating at 100 ℃ for 5min, and taking 5 mu l as a template to be tested to obtain a sample 1 to be tested and a sample 2 to be tested.
SMN1-W and SMN1-M were ligated to pUC57 vector, respectively, and diluted to 1 ng/. mu.l as positive controls; sterile ultrapure water was used as a negative control.
By using LAMP technology, respectively adding 5 mul of sample to be detected 1, 5 mul of sample to be detected 2, 5 mul of positive control and 5 mul of negative control into a system formed by the kit, and reacting the whole reaction system for 60 cycles under the conditions of 65 ℃ for 45sec and 65 ℃ for 15sec (fluorescence collection); then, the reaction was carried out at 85 ℃ for 5min, and SYBR Green I was selected as the fluorescence channel. The response curve judged the genotype of the SMN1 gene.
The detection results of this example are shown in FIG. 3, and it can be seen from FIG. 3 that FIP-W can specifically amplify SMN1-W, while FIP-M specifically amplifies SMN1-M, the result of sample 1 (curve C) shows that the genotype is homozygous and normal, and the result of sample 2 (curve D) shows that the genotype is homozygous and mutated.
Comparative example 1
This comparative example differs from example 1 in that: the additive in the kit is 0.1mol/L trehalose. The comparative example was conducted in the same manner as in example 1, and the results are shown in FIG. 4. It can be seen that, when 0.1mol/L trehalose was used alone as an additive, although specific detection could be achieved, the amplification efficiency was significantly reduced compared to example 1.
Comparative example 2
This comparative example differs from example 1 in that: the additive in the kit is 0.5mg/ml BSA. The comparative example was conducted in the same manner as in example 1, and the results are shown in FIG. 5. Although specific detection could be achieved by using 0.5mg/ml BSA alone as an additive, the amplification efficiency was significantly reduced compared to example 1.
When the results of the tests of example 1, comparative example 1 and comparative example 2 were combined, it was found that trehalose and BSA, which are used alone, slightly inhibited the reaction. However, trehalose and BSA did not show an inhibitory effect when used in combination.
Comparative example 3
This comparative example differs from example 1 in that: in the kit of this comparative example, the primers FIP and BIP have no auxiliary mutant base, and the remaining primers are the same as in example 1, namely:
FIP-W:5’-TGCTGGCAGACTTACTCCTTAA-CTTTATTTTCCTTACAGGGTTTC-3’；
FIP-M:5’-TGCTGGCAGACTTACTCCTTAA-CTTTATTTTCCTTACAGGGTTTT-3’；
BIP-W:5’-TGAAAGTGAATCTTACTTTTGTAAAA-GTTTTACATTAACCTTTCAACTTTT-3’。
the comparative example was conducted in the same manner as in example 1, and the results are shown in FIG. 6. It can be seen that the primers without the auxiliary mutant bases can not distinguish the wild type from the mutant type at all, and the genotype of the sample to be detected is judged to be a carrier according to the detection result of the group of primers; when the auxiliary mutant base is adjacent to the site to be detected, the wild type primer only amplifies the wild type template, and the mutant type primer only amplifies the mutant type template, so that the wild type and the mutant type can be obviously distinguished.
Comparative example 4
This comparative example differs from example 1 in that: in the kit of the comparative example, the positions of the auxiliary mutant bases in the primers FIP and BIP are as follows:
FIP-W:5’-TGCTGGCAGACTTACTCCTTAA-CTTTATTTTCCTTACAGGGTVTC-3’；
FIP-M:5’-TGCTGGCAGACTTACTCCTTAA-CTTTATTTTCCTTACAGGGTVTT-3’；
BIP-W:5’-TGAAAGTGAATCTTACTTTTGTAAAAGTTTTACATTAACCTTTCAACTVTT-3’。
the comparative example was conducted in the same manner as in example 1, and the results are shown in FIG. 7. It can be seen that when the auxiliary mutant base is 1-2 bases away from the site to be detected, the amplification efficiency of the wild type primer on the mutant template is obviously reduced, but the amplification efficiency is only 5-10 min at the time interval, which is not beneficial to distinguishing two genotypes.
Nucleotide or amino acid sequence listing
<110> university of Shanxi university
<120> SMN1 gene detection primer group, kit and detection method capable of eliminating interference of SMN2
<160>
<210>1
<211>23
<212>F3
<213>DNA
<220>
<400>
5'-GCTATCTATGTCTATATAGCTAT-3'
<210>2
<211>24
<212>B3
<213>DNA
<220>
<400>
5'-GTTTTGGCATCAAAATTCTTTAAT-3'
<210>3
<211>45
<212>FIP-W
<213>DNA
<220>
<400>
5'-TGCTGGCAGACTTACTCCTTAACTTTATTTTCCTTACAGGGTTVC-3'
<210>4
<211>45
<212>FIP-M
<213>DNA
<220>
<400>
5'-TGCTGGCAGACTTACTCCTTAACTTTATTTTCCTTACAGGGTTVT-3'
<210>5
<211>51
<212>BIP-W
<213>DNA
<220>
<400>
5'-TGAAAGTGAATCTTACTTTTGTAAAAGTTTTACATTAACCTTTCAACTTVT-3'
<210>6
<211>21
<212>LF
<213>DNA
<220>
<400>
5'-GTGAGCACCTTCCTTCTTTTT-3'
<210>7
<211>23
<212>LB
<213>DNA
<220>
<400>
5'-GTGGAAAACAAATGTTTTTGAAC-3'
<210>8
<211>589
<212>SMN1
<213>DNA
<220>
<400>
5'-AAGTGATCCCCCTACCTCCGCCTCCCAAAGTTGTGGGATTGTAGGCATGAGCCACTGCAAGAAAACCTTAACTGCAGCCTAATAATTGTTTTCTTTGGGATAACTTTTAAAGTACATTAAAAGACTATCAACTTAATTTCTGATCATATTTTGTTGAATAAAATAAGTAAAATGTCTTGTGAAACAAAATGCTTTTTAACATCCATATAAAGCTATCTATATATAGCTATCTATGTCTATATAGCTATTTTTTTTAACTTCCTTTATTTTCCTTACAGGGTTTCAGACAAAATCAAAAAGAAGGAAGGTGCTCACATTCCTTAAATTAAGGAGTAAGTCTGCCAGCATTATGAAAGTGAATCTTACTTTTGTAAAACTTTATGGTTTGTGGAAAACAAATGTTTTTGAACATTTAAAAAGTTCAGATGTTAAAAAGTTGAAAGGTTAATGTAAAACAATCAATATTAAAGAATTTTGATGCCAAAACTATTAGATAAAAGGTTAATCTACATCCCTACTAGAATTCTCATACTTAACTGGTTGGTTATGTGGAAGAAACATACTTTCACAATAAAGAGCTTTAGGATAT-3'
<210>9
<211>589
<212>SMN2
<213>DNA
<220>
<400>
5'-AAGTGATCCCCCTACCTCCGCCTCCCAAAGTTGTGGGATTGTAGGCATGAGCCACTGCAAGAAAACCTTAACTGCAGCCTAATAATTGTTTTCTTTGGGATAACTTTTAAAGTACATTAAAAGACTATCAACTTAATTTCTGATCATATTTTGTTGAATAAAATAAGTAAAATGTCTTGTGAAACAAAATGCTTTTTAACATCCATATAAAGCTATCTATATATAGCTATCTATGTCTATATAGCTATTTTTTTTAACTTCCTTTATTTTCCTTACAGGGTTTTAGACAAAATCAAAAAGAAGGAAGGTGCTCACATTCCTTAAATTAAGGAGTAAGTCTGCCAGCATTATGAAAGTGAATCTTACTTTTGTAAAACTTTATGGTTTGTGGAAAACAAATGTTTTTGAACATTTAAAAAGTTCAGATGTTAAAAAGTTGAAAGGTTAATGTAAAACAATCAATATTAAAGAATTTTGATGCCAAAACTATTAGATAAAAGGTTAATCTACATCCCTACTAGAATTCTCATACTTAACTGGTTGGTTATGTGGAAGAAACATACTTTCACAATAAAGAGCTTTAGGATAT-3'
Claims (8)
1. A primer group for SMN1 gene detection capable of eliminating SMN2 interference, wherein the primer group comprises the following 7 primers;
F3：5’-GCTATCTATGTCTATATAGCTAT-3’；
B3：5’-GTTTTGGCATCAAAATTCTTTAAT-3’；
FIP-W:5’-TGCTGGCAGACTTACTCCTTAACTTTATTTTCCTTACAGGGTTVC-3’；
FIP-M:5’-TGCTGGCAGACTTACTCCTTAACTTTATTTTCCTTACAGGGTTVT-3’；
BIP-W:5’-TGAAAGTGAATCTTACTTTTGTAAAAGTTTTACATTAACCTTTCAACTTVT-3’；
LF：5’-GTGAGCACCTTCCTTCTTTTT-3’；
LB：5’-GTGGAAAACAAATGTTTTTGAAC-3’。
2. a kit for SMN1 gene detection that excludes SMN2 interference, comprising the primer set of claim 1.
3. The kit for detecting SMN1 gene that excludes SMN2 interference according to claim 2, wherein the kit further comprises Bst DNA Polymerase, dntps, a buffer, an indicator and an additive;
the buffer solution comprises Tris-HCl, KCl and (NH)4)2SO4、MgSO4And Tween-20;
the indicator is SYBR Green I solution or Calcein solution and MnCl2A mixed solution of the solution;
the additive comprises trehalose and BSA.
4. The kit for SMN1 gene detection capable of eliminating SMN2 interference of claim 3, wherein the concentration of the primers F3 and B3 is the same and is 0.8-1.6. mu. mol/L, the concentration of LF and LB is the same and is 1.6-3.2. mu. mol/L, and the concentration of FIP-W, FIP-M, BIP-W is the same and is 1.6-3.2. mu. mol/L.
5. The kit for detecting SMN1 gene that excludes SMN2 interference as set forth in claim 3, wherein said Bst DNA polymerase0.3-0.4U/. mu.l; the dNTP is 1.0-3.5 mmol/L;
the buffer solution contains 10-50 mmol/L, KCl of Tris-HCl 10-100 mmol/L and (NH)4)2SO45 to 20mmol/L, MgSO4The buffer solution accounts for 0.1-0.5% of the buffer solution by mass of 6-10 mmol/L, Tween-20.
6. The kit for SMN1 gene detection that excludes SMN2 interference according to claim 3, wherein the concentration of SYBR Green I is 1X to 5X; the Calcein and the MnCl2The concentration of the Calcein solution in the mixed solution is 10-30 mu mol/L, and the mixed solution is MnCl2The solution was 500. mu. mol/L.
7. The kit for SMN1 gene detection capable of eliminating SMN2 interference as claimed in claim 3, wherein the trehalose is 0.1-0.3 mol/L and the BSA is 0.2-1 mg/ml.
8. A method for detecting an SMN1 gene which can exclude interference of SMN2, comprising the steps of:
placing the oral swab into 200 mul TE buffer solution, vortex and shake for 1min, and heating at 100 ℃ for 5min to obtain a template to be tested; the SMN1-W and SMN1-M genes were ligated to pUC57 vector, respectively, and diluted to 1 ng/. mu.l as positive controls; sterile ultrapure water was used as a negative control;
respectively adding a template to be tested, a positive control and a negative control into the kit system of any one of claims 2-7 by using LAMP technology, and reacting the whole reaction system for 60 cycles under the conditions of 65 ℃ for 45sec and 65 ℃ for 15 sec; then, the reaction was carried out at 85 ℃ for 5min, and the genotype of the SMN1 gene was determined from the reaction curve.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010058927.6A CN111187826A (en) | 2020-01-19 | 2020-01-19 | SMN1 gene detection primer group capable of eliminating SMN2 interference, kit and detection method |
| CN202310648533.XA CN116479116A (en) | 2020-01-19 | 2020-01-19 | Kit and method for detecting SMN1 gene capable of eliminating SMN2 interference |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010058927.6A CN111187826A (en) | 2020-01-19 | 2020-01-19 | SMN1 gene detection primer group capable of eliminating SMN2 interference, kit and detection method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310648533.XA Division CN116479116A (en) | 2020-01-19 | 2020-01-19 | Kit and method for detecting SMN1 gene capable of eliminating SMN2 interference |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111187826A true CN111187826A (en) | 2020-05-22 |
Family
ID=70706443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010058927.6A Pending CN111187826A (en) | 2020-01-19 | 2020-01-19 | SMN1 gene detection primer group capable of eliminating SMN2 interference, kit and detection method |
| CN202310648533.XA Pending CN116479116A (en) | 2020-01-19 | 2020-01-19 | Kit and method for detecting SMN1 gene capable of eliminating SMN2 interference |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310648533.XA Pending CN116479116A (en) | 2020-01-19 | 2020-01-19 | Kit and method for detecting SMN1 gene capable of eliminating SMN2 interference |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111187826A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116179679A (en) * | 2022-11-07 | 2023-05-30 | 嘉检(广州)生物工程技术有限公司 | Detection primer pair and detection probe of SMN1 gene and kit for detecting spinal muscular atrophy |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105821138A (en) * | 2016-05-12 | 2016-08-03 | 陕西师范大学 | Method for constructing double-stem-loop structure DNA template to detect nucleic acid based on ligation reaction |
| US20160289752A1 (en) * | 2015-03-31 | 2016-10-06 | Transponics | Method for the Isothermic Amplification of Nucleic Acid and SNP Detection |
| CN106676190A (en) * | 2017-03-02 | 2017-05-17 | 陈万金 | Spinal muscular atrophy related gene mutation detection kit and application thereof |
| CN107523642A (en) * | 2017-10-20 | 2017-12-29 | 苏州旷远生物分子技术有限公司 | A kind of chain reaction of multiple reverse transcription polymerase detection reagent buffer solution and its application |
| CN108504721A (en) * | 2018-04-02 | 2018-09-07 | 湖南大学 | A kind of novel individualized treatment gene tester |
| CN108998505A (en) * | 2018-07-30 | 2018-12-14 | 苏州先达基因科技有限公司 | A kind of gene polymorphism sites detection technique and its kit |
| CN110172500A (en) * | 2019-05-31 | 2019-08-27 | 中国科学院成都生物研究所 | A kind of isothermal classifying method of single nucleotide polymorphism |
-
2020
- 2020-01-19 CN CN202010058927.6A patent/CN111187826A/en active Pending
- 2020-01-19 CN CN202310648533.XA patent/CN116479116A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160289752A1 (en) * | 2015-03-31 | 2016-10-06 | Transponics | Method for the Isothermic Amplification of Nucleic Acid and SNP Detection |
| CN105821138A (en) * | 2016-05-12 | 2016-08-03 | 陕西师范大学 | Method for constructing double-stem-loop structure DNA template to detect nucleic acid based on ligation reaction |
| CN106676190A (en) * | 2017-03-02 | 2017-05-17 | 陈万金 | Spinal muscular atrophy related gene mutation detection kit and application thereof |
| CN107523642A (en) * | 2017-10-20 | 2017-12-29 | 苏州旷远生物分子技术有限公司 | A kind of chain reaction of multiple reverse transcription polymerase detection reagent buffer solution and its application |
| CN108504721A (en) * | 2018-04-02 | 2018-09-07 | 湖南大学 | A kind of novel individualized treatment gene tester |
| CN108998505A (en) * | 2018-07-30 | 2018-12-14 | 苏州先达基因科技有限公司 | A kind of gene polymorphism sites detection technique and its kit |
| CN110172500A (en) * | 2019-05-31 | 2019-08-27 | 中国科学院成都生物研究所 | A kind of isothermal classifying method of single nucleotide polymorphism |
Non-Patent Citations (2)
| Title |
|---|
| ATHANASE BADOLO ET AL.: ""Detection of G119S ace-1R mutation in feld-collected Anopheles gambiae mosquitoes using allele-specifc loop-mediated isothermal amplifcation (AS-LAMP) method"", 《MALARIA JOURNAL》 * |
| 江雨等: ""脊髓性肌萎缩症SMN1基因携带者筛查技术研究进展"", 《中国产前诊断杂志（电子版）》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116179679A (en) * | 2022-11-07 | 2023-05-30 | 嘉检(广州)生物工程技术有限公司 | Detection primer pair and detection probe of SMN1 gene and kit for detecting spinal muscular atrophy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116479116A (en) | 2023-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3246332B1 (en) | Oligonucleotides and methods for detecting pik3ca mutations | |
| CN111118151A (en) | Human SMN1 and SMN2 gene copy number detection kit based on digital PCR method | |
| US20130078631A1 (en) | Probe, and polymorphism detection method using the same | |
| EP2578701A1 (en) | Probe, polymorphism detection method, method of evaluating drug efficacy or tolerance, and reagent kit | |
| KR20130123364A (en) | Highly sensitive mutated gene detection method | |
| JP2003534812A (en) | Detection of nucleotide sequence variation by restriction primer extension | |
| EP2839039B1 (en) | Hev assay | |
| CN111172273B (en) | Primer group, kit and detection method for SMN1 gene detection | |
| KR20130029748A (en) | Method for detecting mutations at il28b(rs8099917) and itpa(rs1127354) | |
| JPWO2009011297A1 (en) | Probe for detecting mutation in JAK2 gene and use thereof | |
| CN108060213B (en) | Probe and kit for detecting SNP (single nucleotide polymorphism) sites by recombinase-mediated isothermal amplification method based on probe guidance | |
| EP2450443B1 (en) | Target sequence amplification method, polymorphism detection method, and reagents for use in the methods | |
| WO2012020965A2 (en) | Pik3ca mutation detection method and kit using real-time pcr clamping of pna | |
| CN111187826A (en) | SMN1 gene detection primer group capable of eliminating SMN2 interference, kit and detection method | |
| JPWO2007105673A1 (en) | Mutant gene detection method | |
| US20010039012A1 (en) | Methods for diagnostic screening | |
| US9255298B2 (en) | Probe, and polymorphism detection method using the same | |
| EP3279338A1 (en) | Gene mutation detection method and fluorescence-labeled oligonucleotide used in same | |
| US20130005589A1 (en) | Highly sensitive method for detecting mutated gene | |
| CN109182563B (en) | Method for detecting 20 drug resistance genes of dfrA trimethoprim drugs and kit used in method | |
| WO2012002447A1 (en) | Method for detection of mutated polynucleotide | |
| EP2643461B1 (en) | Methods, compositions, and kits for determining hepatitis a virus | |
| CN111187805B (en) | Design method and application of auxiliary mutation primer | |
| JP5860667B2 (en) | Primer set for detecting EGFR exon 21L858R gene polymorphism and use thereof | |
| EP3845666A1 (en) | A method of detecting small rna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200522 |
|
| RJ01 | Rejection of invention patent application after publication |